Loading
JPXHealthcareBiotechnology
Latest quote
¥850
−¥26.00 · -2.97%
Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support. It manufactures and delivers autologous cultured tissues, such as epidermis, cartilage, corneal epithelium, and oral mucosal epithelium, to medical institutions for therapeutic applications. The firm also produces other advanced tissue-engineered medical products. Furthermore, Japan Tissue Engineering is involved in the research and development of three-dimensional human cultured tissue models, which are utilized in the development of external-use cosmetics and drugs, as well as for scientific investigations concerning skin and corneal tissues. Additionally, the company provides comprehensive contract development and manufacturing services for regenerative medicine. Established in 1999, Japan Tissue Engineering Co., Ltd. is based in Gamagori, Japan, and functions as a subsidiary of Teijin Limited.
Latest quote
¥850
−¥26.00 · -2.97%
Regular session · JST · Market data may be delayed.
Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support. It manufactures and delivers autologous cultured tissues, such as epidermis, cartilage, corneal epithelium, and oral mucosal epithelium, to medical institutions for therapeutic applications. The firm also produces other advanced tissue-engineered medical products. Furthermore, Japan Tissue Engineering is involved in the research and development of three-dimensional human cultured tissue models, which are utilized in the development of external-use cosmetics and drugs, as well as for scientific investigations concerning skin and corneal tissues. Additionally, the company provides comprehensive contract development and manufacturing services for regenerative medicine. Established in 1999, Japan Tissue Engineering Co., Ltd. is based in Gamagori, Japan, and functions as a subsidiary of Teijin Limited.
Day range
Current ¥850
52-week range
Current ¥850
Regular session · JST · Market data may be delayed.
Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support. It manufactures and delivers autologous cultured tissues, such as epidermis, cartilage, corneal epithelium, and oral mucosal epithelium, to medical institutions for therapeutic applications. The firm also produces other advanced tissue-engineered medical products. Furthermore, Japan Tissue Engineering is involved in the research and development of three-dimensional human cultured tissue models, which are utilized in the development of external-use cosmetics and drugs, as well as for scientific investigations concerning skin and corneal tissues. Additionally, the company provides comprehensive contract development and manufacturing services for regenerative medicine. Established in 1999, Japan Tissue Engineering Co., Ltd. is based in Gamagori, Japan, and functions as a subsidiary of Teijin Limited.
Day range
Current ¥850
52-week range
Current ¥850
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.18B JPY | 2.46B JPY | 2.51B JPY | 2.03B JPY | 2.1B JPY |
| Cost of goods sold | 956.6M JPY | 986.16M JPY | 847.41M JPY | 917.2M JPY | 865.8M JPY |
| Gross profit | 1.23B JPY | 1.47B JPY | 1.67B JPY | 1.12B JPY | 1.24B JPY |
| Research and development | 497.32M JPY | 506.73M JPY | 407.01M JPY | 573.32M JPY | 561.86M JPY |
| Selling, general, and administrative | 1.24B JPY | 1.14B JPY | 1.06B JPY | 1.22B JPY | 1.12B JPY |
| Operating expenses | 1.78B JPY | 1.71B JPY | 1.52B JPY | 1.84B JPY | 1.74B JPY |
| Interest income | 9.78M JPY | 2.61M JPY | 782K JPY | 1.14M JPY | 2.4M JPY |
| Depreciation and amortization | 157.38M JPY | 113.58M JPY | 97.81M JPY | 131.45M JPY | 124.97M JPY |
| Operating income | −549.45M JPY | −238.32M JPY | 144.51M JPY | −728.12M JPY | −498.18M JPY |
| Net income | −734.75M JPY | −255.3M JPY | 143.17M JPY | −729.32M JPY | −497.89M JPY |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 27, 2014 | 200:1 | — | — |
Effective Mar 27, 2014
200:1
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
